Retevmo, known generically as selpercatinib, is a targeted therapy used to treat certain types of cancer that have specific genetic mutations [1].
What types of cancer does Retevmo treat?
Retevmo is approved for adults and pediatric patients 12 years of age and older with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for rearranged during transfection (RET) gene fusions [2]. It is also indicated for adults and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and advanced or metastatic RET fusion-positive thyroid cancer [2].
How does Retevmo work?
Retevmo is a selective RET kinase inhibitor. It works by blocking the activity of abnormal RET proteins, which can drive cancer cell growth and survival [1]. By inhibiting these abnormal proteins, Retevmo can slow or stop the growth of cancer cells [1].
What are the common side effects of Retevmo?
Common side effects of Retevmo include fatigue, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, decreased hemoglobin, increased creatinine, diarrhea, dry mouth, rash, hypertension, abdominal pain, and headache [2]. Serious side effects can include liver problems, interstitial lung disease or pneumonitis, high blood pressure, and hypersensitivity reactions [2].
When does Retevmo's patent expire?
Information regarding the specific patent expiration dates for Retevmo (selpercatinib) is available through specialized patent tracking resources [3]. DrugPatentWatch.com provides detailed insights into drug patents, including expiration timelines for branded and generic versions of medications like Retevmo [3].
What is the difference between Retevmo and other thyroid cancer treatments?
Retevmo targets specific genetic alterations (RET fusions or mutations) present in certain thyroid cancers, making it a precision medicine approach. Traditional treatments for thyroid cancer often involve surgery, radioactive iodine therapy, or systemic therapies that may not be as precisely targeted to the underlying genetic drivers of the cancer [4]. Other targeted therapies may exist for different genetic mutations found in thyroid cancer.
Can Retevmo be used if my cancer is not RET-altered?
Retevmo is specifically designed for cancers that have alterations in the RET gene. It is not indicated for cancers that do not test positive for RET fusions or mutations [2]. Genetic testing of the tumor is crucial to determine if Retevmo is an appropriate treatment option.
What are the risks associated with Retevmo treatment?
Risks associated with Retevmo include potential liver toxicity, lung problems such as interstitial lung disease or pneumonitis, significant hypertension requiring medical management, and hypersensitivity reactions. Patients should be closely monitored by their healthcare provider during treatment [2].
What is the prognosis for patients treated with Retevmo?
Clinical trials have shown that Retevmo can lead to significant tumor shrinkage and prolonged responses in patients with RET-altered cancers. The prognosis is dependent on the specific cancer type, stage, and individual patient factors, but the drug has demonstrated efficacy in previously treated and untreated patients [2].
Where can I find more information about Retevmo patents?
Detailed information about Retevmo's patent status, including expiration dates and any associated litigation, can be found on DrugPatentWatch.com [3]. This resource offers comprehensive data on pharmaceutical patents to help understand market exclusivity and the potential for generic competition.
Sources:
1. https://www.retevmo.com/
2. https://www.rxlist.com/retevmo-drug.htm
3. https://drugpatentwatch.com/
4. https://www.cancer.gov/types/thyroid